Starforma has entered into a basic agreement with QST Hospital for the development of new particle beam therapy technologies. The company is exploring a new cancer treatment that combines boron pharmaceuticals and particle beams, with minimal impact expected on the performance for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Starforma Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4888-20260728-01.pdf","jir_short_summary":"Starforma has entered into a basic agreement with QST Hospital for the development of new particle beam therapy technologies. The company is exploring a new cancer treatment that combines boron pharmaceuticals and particle beams, with minimal impact expected on the performance for the fiscal year ending March 2027.","jir_summary":"### Overview of Business Strategy and Partnership\nStarforma has signed a basic agreement with the National Institutes for Quantum Science and Technology (QST) Hospital to establish a collaborative research contract. This collaboration will explore a new cancer treatment method combining the company's BNCT drug 'Estborrowin\u00ae', which is manufactured and sold by the company, with particle research equipment owned by QST. Unlike conventional BNCT, this approach investigates a new mechanism of action utilizing particle beams, progressing from basic research through clinical trials with the aim of obtaining pharmaceutical approval. Details are expected to become clearer as research progresses and further contractual developments are made.\n\n### Future Outlook and Impact on Investors\nThe direct impact on performance for the fiscal year ending March 2027 is expected to be minimal; however, it could serve as a significant step towards the realization of new cancer treatment technologies in the long term. The company plans to continue discussions with QST and will provide timely updates on research progress and disclosures. This initiative is of interest to investors as a development in innovative medical technology.","jir_financial_highlights":"Impact on performance for the fiscal year ending March 2027: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Starforma, #IRRelated, #JapanStocks","jir_key_figures":"Signing of collaborative research contract: July 28, 2026\nImpact on performance for the fiscal year ending March 2027: Unknown\nPartner: QST Hospital","jir_meta_title":"[Starforma] New Particle Beam Therapy Collaboration\uff5cJuly 2026","jir_meta_description":"Starforma has signed a basic agreement with QST Hospital for new particle beam therapy. The company has initiated joint research toward innovative cancer treatments, with minimal expected impact on 2027 performance.","jir_og_title":"[Starforma] Particle Beam Therapy Partnership\uff5cJuly 2026","jir_og_description":"Starforma and QST Hospital have signed a basic agreement on new cancer treatment technologies. Expectations are high for their contribution to long-term medical innovation.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-88878","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n